About Malaika Alphonsus

Malaika's passion for writing and interest in financial markets led her to pursue a career in investment research.

With a degree in Economics and Psychology, she intends to assist investors in making informed investment decisions.


Recent Articles By Malaika Alphonsus

: ABBV |  News, Ratings, and Charts

AbbVie (ABBV) and Catalyst Pharmaceuticals (CPRX): Analyzing Investment Potential

The pharmaceutical industry’s inelastic demand for its products helps it to weather economic downturns. With fears of an impending recession playing on the minds of investors, it could be wise to buy fundamentally strong pharmaceutical stock AbbVie (ABBV). On the other hand, given its mixed fundamentals and profitability, it could be wise to add Catalyst Pharmaceuticals (CPRX) to one’s watchlist. Keep reading...
: CNQ |  News, Ratings, and Charts

Looking for Stable Income? Keep an Eye on These 3 Dividend Stocks

Amid macroeconomic headwinds of restrictive monetary policy and tighter credit standards, market volatility is expected to persist. Amid this backdrop, it could be wise to add dividend-paying stocks Canadian Natural Resources (CNQ), Eastman Chemical (EMN), and Whirlpool (WHR) to one’s watchlist. Keep reading...
: QS |  News, Ratings, and Charts

Is QuantumScape (QS) a Buy This Week?

The transition to electric vehicles is driving the demand for batteries that will last longer, provide fast charging, and have a more extended range. QuantumScape Corporation’s (QS) solid-state batteries hold immense promise to change the EV industry forever. So, will it be wise to buy the stock this week? Read on to learn my view. Keep reading...
: VRTX |  News, Ratings, and Charts

3 Momentum Stocks to Buy Now

The market remains volatile amid macroeconomic pressures and fears of an impending recession. However, fundamentally strong stocks Vertex Pharmaceuticals (VRTX), US Foods Holding (USFD), and Vontier (VNT) have gained momentum and could be worth buying. Keep reading...
: GE |  News, Ratings, and Charts

Does General Electric (GE) Belong in Your Portfolio?

Although the current macroeconomic climate has been challenging for the industrial sector, General Electric (GE) reported a solid first-quarter performance. Moreover, the company is expected to continue its strong momentum as it raises its earnings and free cash flow estimates. Therefore, it could be wise to add the stock to one’s portfolio. Keep reading...
: ASX |  News, Ratings, and Charts

3 Chip Stocks Investors Want

Despite facing several macroeconomic headwinds over the past year, the chip sector is well-positioned for growth in the long term. To that end, investors could look to buy fundamentally strong chip stocks ASE Technology Holding (ASX), Cohu (COHU), and Veeco Instruments (VECO). Keep reading...
: MAR |  News, Ratings, and Charts

Is Marriott International (MAR) a Good Long-term Buy?

Despite a challenging macroeconomic climate, Marriott (MAR) reported a strong financial performance in the first quarter and raised its RevPAR guidance for the rest of the year. With the company likely to benefit from high demand for travel and hospitality, investors could buy the fundamentally strong stock for the long term. Keep reading...
: LZB |  News, Ratings, and Charts

3 Home Good Stocks to Buy

With homeownership increasing and consumer preferences constantly changing, the demand for home improvement goods is anticipated to rise in the long term. Therefore, investors could look to buy fundamentally strong home improvement stocks La-Z-Boy (LZB), HNI Corporation (HNI), and Ethan Allen Interiors (ETD). Keep reading...
: JKS |  News, Ratings, and Charts

Is JinkoSolar Holding (JKS) the Best Buy for Solar Stocks?

With growing adoption of renewable energy sources such as solar power, companies producing various solar components for solar energy production are likely to be in high demand. Amid this backdrop, will buying JinkoSolar (JKS) be wise? Read more to learn my view...
: BCYC |  News, Ratings, and Charts

3 Biotech Stocks Losing Market Value

There is a growing demand for healthcare solutions, and the biotech industry will likely benefit from it. However, not all biotech stocks are well-positioned to capitalize on the industry tailwinds. Therefore, investors could look to avoid fundamentally weak biotech stocks Bicycle Therapeutics (BCYC), CorMedix (CRMD), and 22nd Century Group (XXII). Keep reading...
Page generated in 1.47 seconds.